Calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts

Nina Fenouille, Sebastien Grosso, Yunchao Su, Mary Didier, Rodolphe Pontier-Bres, Véronique Imbert, Dorota Czerucka, François Xavier Caroli-Bosc, Jean François Peyron, Patricia Lagadec

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

CPT-11 (irinotecan), the first-line chemotherapy for advanced stage colorectal cancer, remains inactive in about half of patients (primary chemoresistance) and almost all initial responders develop secondary resistance after several courses of treatment (8 months on average). Nude mice bearing HT-29 colon cancer xenografts were treated with CPT-11 and/or an NF-κB inhibitor for two courses. We confirm that NF-κB inhibition potentiated CPT-11 anti-tumoural effect after the first course of treatment. However, tumours grew again at the end of the second course of treatment, generating resistant tumours. We observed an increase in the basal NF-κB activation in resistant tumours and in two resistant sublines, either obtained from resistant HT-29 tumours (HT-29R cells) or generated in vitro (RSN cells). The decrease of NF-κB activation in HT-29R and RSN cells by stable transfections with the super-repressor form of IκBα augmented their sensitivity to CPT-11. Comparing gene expression profiles of HT-29 and HT-29R cells, we identified the S100A10/Annexin A2 complex and calpain 2 as over-expressed potential NF-κB inducers. SiRNA silencing of calpain 2 but not of S100A10 and/or annexin A2, resulted in a decrease in NF-κB activation, an increase in cellular levels of IκBα and a partial restoration of the CPT-11 sensitivity in both HT-29R and RSN cells, suggesting that calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance. Thus, targeted therapies directed against calpain 2 may represent a novel strategy to enhance the anti-cancer efficacy of CPT-11.

Original languageEnglish (US)
Pages (from-to)118-129
Number of pages12
JournalJournal of Pathology
Volume227
Issue number1
DOIs
StatePublished - May 1 2012

Fingerprint

irinotecan
Calpain
Heterografts
Colorectal Neoplasms
Annexin A2
Neoplasms
HT29 Cells
Therapeutics
Transcriptome

Keywords

  • Advanced colorectal cancer
  • Annexin A2
  • Biomarkers
  • CPT-11/SN-38
  • Calpain 2
  • Drug resistance
  • NF-κB
  • S100A10

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Fenouille, N., Grosso, S., Su, Y., Didier, M., Pontier-Bres, R., Imbert, V., ... Lagadec, P. (2012). Calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts. Journal of Pathology, 227(1), 118-129. https://doi.org/10.1002/path.3034

Calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts. / Fenouille, Nina; Grosso, Sebastien; Su, Yunchao; Didier, Mary; Pontier-Bres, Rodolphe; Imbert, Véronique; Czerucka, Dorota; Caroli-Bosc, François Xavier; Peyron, Jean François; Lagadec, Patricia.

In: Journal of Pathology, Vol. 227, No. 1, 01.05.2012, p. 118-129.

Research output: Contribution to journalArticle

Fenouille, N, Grosso, S, Su, Y, Didier, M, Pontier-Bres, R, Imbert, V, Czerucka, D, Caroli-Bosc, FX, Peyron, JF & Lagadec, P 2012, 'Calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts', Journal of Pathology, vol. 227, no. 1, pp. 118-129. https://doi.org/10.1002/path.3034
Fenouille, Nina ; Grosso, Sebastien ; Su, Yunchao ; Didier, Mary ; Pontier-Bres, Rodolphe ; Imbert, Véronique ; Czerucka, Dorota ; Caroli-Bosc, François Xavier ; Peyron, Jean François ; Lagadec, Patricia. / Calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts. In: Journal of Pathology. 2012 ; Vol. 227, No. 1. pp. 118-129.
@article{8622f9268f2040488590b43198e31399,
title = "Calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts",
abstract = "CPT-11 (irinotecan), the first-line chemotherapy for advanced stage colorectal cancer, remains inactive in about half of patients (primary chemoresistance) and almost all initial responders develop secondary resistance after several courses of treatment (8 months on average). Nude mice bearing HT-29 colon cancer xenografts were treated with CPT-11 and/or an NF-κB inhibitor for two courses. We confirm that NF-κB inhibition potentiated CPT-11 anti-tumoural effect after the first course of treatment. However, tumours grew again at the end of the second course of treatment, generating resistant tumours. We observed an increase in the basal NF-κB activation in resistant tumours and in two resistant sublines, either obtained from resistant HT-29 tumours (HT-29R cells) or generated in vitro (RSN cells). The decrease of NF-κB activation in HT-29R and RSN cells by stable transfections with the super-repressor form of IκBα augmented their sensitivity to CPT-11. Comparing gene expression profiles of HT-29 and HT-29R cells, we identified the S100A10/Annexin A2 complex and calpain 2 as over-expressed potential NF-κB inducers. SiRNA silencing of calpain 2 but not of S100A10 and/or annexin A2, resulted in a decrease in NF-κB activation, an increase in cellular levels of IκBα and a partial restoration of the CPT-11 sensitivity in both HT-29R and RSN cells, suggesting that calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance. Thus, targeted therapies directed against calpain 2 may represent a novel strategy to enhance the anti-cancer efficacy of CPT-11.",
keywords = "Advanced colorectal cancer, Annexin A2, Biomarkers, CPT-11/SN-38, Calpain 2, Drug resistance, NF-κB, S100A10",
author = "Nina Fenouille and Sebastien Grosso and Yunchao Su and Mary Didier and Rodolphe Pontier-Bres and V{\'e}ronique Imbert and Dorota Czerucka and Caroli-Bosc, {Fran{\cc}ois Xavier} and Peyron, {Jean Fran{\cc}ois} and Patricia Lagadec",
year = "2012",
month = "5",
day = "1",
doi = "10.1002/path.3034",
language = "English (US)",
volume = "227",
pages = "118--129",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts

AU - Fenouille, Nina

AU - Grosso, Sebastien

AU - Su, Yunchao

AU - Didier, Mary

AU - Pontier-Bres, Rodolphe

AU - Imbert, Véronique

AU - Czerucka, Dorota

AU - Caroli-Bosc, François Xavier

AU - Peyron, Jean François

AU - Lagadec, Patricia

PY - 2012/5/1

Y1 - 2012/5/1

N2 - CPT-11 (irinotecan), the first-line chemotherapy for advanced stage colorectal cancer, remains inactive in about half of patients (primary chemoresistance) and almost all initial responders develop secondary resistance after several courses of treatment (8 months on average). Nude mice bearing HT-29 colon cancer xenografts were treated with CPT-11 and/or an NF-κB inhibitor for two courses. We confirm that NF-κB inhibition potentiated CPT-11 anti-tumoural effect after the first course of treatment. However, tumours grew again at the end of the second course of treatment, generating resistant tumours. We observed an increase in the basal NF-κB activation in resistant tumours and in two resistant sublines, either obtained from resistant HT-29 tumours (HT-29R cells) or generated in vitro (RSN cells). The decrease of NF-κB activation in HT-29R and RSN cells by stable transfections with the super-repressor form of IκBα augmented their sensitivity to CPT-11. Comparing gene expression profiles of HT-29 and HT-29R cells, we identified the S100A10/Annexin A2 complex and calpain 2 as over-expressed potential NF-κB inducers. SiRNA silencing of calpain 2 but not of S100A10 and/or annexin A2, resulted in a decrease in NF-κB activation, an increase in cellular levels of IκBα and a partial restoration of the CPT-11 sensitivity in both HT-29R and RSN cells, suggesting that calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance. Thus, targeted therapies directed against calpain 2 may represent a novel strategy to enhance the anti-cancer efficacy of CPT-11.

AB - CPT-11 (irinotecan), the first-line chemotherapy for advanced stage colorectal cancer, remains inactive in about half of patients (primary chemoresistance) and almost all initial responders develop secondary resistance after several courses of treatment (8 months on average). Nude mice bearing HT-29 colon cancer xenografts were treated with CPT-11 and/or an NF-κB inhibitor for two courses. We confirm that NF-κB inhibition potentiated CPT-11 anti-tumoural effect after the first course of treatment. However, tumours grew again at the end of the second course of treatment, generating resistant tumours. We observed an increase in the basal NF-κB activation in resistant tumours and in two resistant sublines, either obtained from resistant HT-29 tumours (HT-29R cells) or generated in vitro (RSN cells). The decrease of NF-κB activation in HT-29R and RSN cells by stable transfections with the super-repressor form of IκBα augmented their sensitivity to CPT-11. Comparing gene expression profiles of HT-29 and HT-29R cells, we identified the S100A10/Annexin A2 complex and calpain 2 as over-expressed potential NF-κB inducers. SiRNA silencing of calpain 2 but not of S100A10 and/or annexin A2, resulted in a decrease in NF-κB activation, an increase in cellular levels of IκBα and a partial restoration of the CPT-11 sensitivity in both HT-29R and RSN cells, suggesting that calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance. Thus, targeted therapies directed against calpain 2 may represent a novel strategy to enhance the anti-cancer efficacy of CPT-11.

KW - Advanced colorectal cancer

KW - Annexin A2

KW - Biomarkers

KW - CPT-11/SN-38

KW - Calpain 2

KW - Drug resistance

KW - NF-κB

KW - S100A10

UR - http://www.scopus.com/inward/record.url?scp=84859631303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859631303&partnerID=8YFLogxK

U2 - 10.1002/path.3034

DO - 10.1002/path.3034

M3 - Article

VL - 227

SP - 118

EP - 129

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 1

ER -